Glycemic characteristics and neonatal outcomes of women treated for mild gestational diabetes
- PMID: 21422852
- PMCID: PMC3282599
- DOI: 10.1097/AOG.0b013e31820fc6cf
Glycemic characteristics and neonatal outcomes of women treated for mild gestational diabetes
Abstract
Objective: To estimate the association between fasting and 2-hour postprandial blood glucose levels and neonatal outcomes in women treated for mild gestational diabetes.
Methods: In this secondary analysis of a multicenter randomized treatment trial of mild gestational diabetes, the median fasting and 2-hour postprandial glucose levels were analyzed in 2-week intervals and change over time (slope) was calculated for women with gestational diabetes (abnormal oral glucose tolerance test) and a fasting glucose less than 95 mg/dL who received nutritional management with self blood glucose monitoring and insulin as needed. Regression analyses were performed to estimate the relationship between median fasting and postprandial glucose and neonatal fat mass, cord blood C-peptide, birth weight, large-for-gestational-age neonates, macrosomia (greater than 4,000 g), and neonatal hypoglycemia.
Results: Among 460 women with gestational diabetes, median fasting (P<.001), postprandial breakfast (P<.001), and postprandial lunch (P<.001) glucose values declined over the treatment period, whereas postprandial dinner values remained stable (P=.83). Higher median fasting glucose during the first 2 weeks of treatment was significantly associated with increased odds ratios for neonatal fat mass (1.35; 95% CI 1.09-1.66; P=.006) and elevated C-peptide (1.29; CI 1.09-1.52; P=.003). Higher median fasting glucose during the last 2 weeks before delivery was associated with higher rates of large-for-gestational-age neonates (1.27; CI 1.05-1.53; P=.01), macrosomia (1.32; CI 1.04-1.65; P = .02), and elevated C-peptide (1.19; CI 1.03-1.38; P=.02).
Conclusion: In women treated for mild gestational diabetes, higher fasting glucose during initiation of diet therapy was associated with increased neonatal fat mass and elevated C-peptide and during the last 2 weeks before delivery with macrosomia, large-for-gestational age, and elevated C-peptide.
Level of evidence: II.
References
-
- The HAPO Study Cooperative Research Group. Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008;358:1991–2002. - PubMed
-
- Jovanovic-Peterson L, Peterson C, Reed GF, Metzger BE, Mills JL, Knopp RH, et al. Maternal postprandial glucose levels and infant birth weight: The Diabetes in Early Pregnancy Study. The National Institute of Child Health and Human Development–Diabetes in Early Pregnancy Study. Am J Obstet Gynecol. 1991;164:103–11. - PubMed
-
- Combs CA, Gunderson E, Kitzmiller JL, Gavin LA, Main EK. Relationship of fetal macrosomia to maternal postprandial glucose control during pregnancy. Diabetes Care. 1992;15:1251–7. - PubMed
-
- de Veciana M, Major CA, Morgan MA, Asrat T, Toohey JS, Lien JM, et al. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med. 1995;333:1237–41. - PubMed
-
- Uvena-Celebrezze J, Fung C, Thomas AJ, Hoty A, Huston-Presley L, Amini SB, et al. Relationship of neonatal body composition to maternal glucose control in women with gestational diabetes mellitus. J Matern Fetal Neonat Med. 2002;12:396–401. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- HD36801/HD/NICHD NIH HHS/United States
- U10 HD040544/HD/NICHD NIH HHS/United States
- U10 HD034136/HD/NICHD NIH HHS/United States
- U10 HD040485/HD/NICHD NIH HHS/United States
- UL1-RR024989/RR/NCRR NIH HHS/United States
- HD40485/HD/NICHD NIH HHS/United States
- HD40560/HD/NICHD NIH HHS/United States
- U01 HD036801/HD/NICHD NIH HHS/United States
- U10 HD053118/HD/NICHD NIH HHS/United States
- UL1 RR024989/RR/NCRR NIH HHS/United States
- U10 HD040500/HD/NICHD NIH HHS/United States
- M01-RR00034/RR/NCRR NIH HHS/United States
- UG1 HD027869/HD/NICHD NIH HHS/United States
- M01 RR000034/RR/NCRR NIH HHS/United States
- UL1-RR025764/RR/NCRR NIH HHS/United States
- UL1 RR025764/RR/NCRR NIH HHS/United States
- UG1 HD034116/HD/NICHD NIH HHS/United States
- HD27869/HD/NICHD NIH HHS/United States
- HD34136/HD/NICHD NIH HHS/United States
- UG1 HD040560/HD/NICHD NIH HHS/United States
- HD53118/HD/NICHD NIH HHS/United States
- UG1 HD053097/HD/NICHD NIH HHS/United States
- HD27860/HD/NICHD NIH HHS/United States
- UG1 HD027915/HD/NICHD NIH HHS/United States
- HD40512/HD/NICHD NIH HHS/United States
- UG1 HD040544/HD/NICHD NIH HHS/United States
- UG1 HD034208/HD/NICHD NIH HHS/United States
- UG1 HD040512/HD/NICHD NIH HHS/United States
- HD40545/HD/NICHD NIH HHS/United States
- U10 HD034116/HD/NICHD NIH HHS/United States
- HD21410/HD/NICHD NIH HHS/United States
- U10 HD027869/HD/NICHD NIH HHS/United States
- U10 HD027917/HD/NICHD NIH HHS/United States
- HD34116/HD/NICHD NIH HHS/United States
- U10 HD027915/HD/NICHD NIH HHS/United States
- UG1 HD040545/HD/NICHD NIH HHS/United States
- UG1 HD040485/HD/NICHD NIH HHS/United States
- U10 HD027860/HD/NICHD NIH HHS/United States
- HD40500/HD/NICHD NIH HHS/United States
- C06 RR011234/RR/NCRR NIH HHS/United States
- U10 HD040560/HD/NICHD NIH HHS/United States
- U10 HD034208/HD/NICHD NIH HHS/United States
- U10 HD053097/HD/NICHD NIH HHS/United States
- HD34208/HD/NICHD NIH HHS/United States
- HD27915/HD/NICHD NIH HHS/United States
- UG1 HD040500/HD/NICHD NIH HHS/United States
- M01-RR00080/RR/NCRR NIH HHS/United States
- R24 HD050924/HD/NICHD NIH HHS/United States
- U10 HD040512/HD/NICHD NIH HHS/United States
- HD27917/HD/NICHD NIH HHS/United States
- U10 HD021410/HD/NICHD NIH HHS/United States
- M01 RR000080/RR/NCRR NIH HHS/United States
- U24 HD036801/HD/NICHD NIH HHS/United States
- U10 HD036801/HD/NICHD NIH HHS/United States
- HD53097/HD/NICHD NIH HHS/United States
- U10 HD040545/HD/NICHD NIH HHS/United States
- HD40544/HD/NICHD NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials